Vitiligo and lipohypertrophy surrounding insulin injection sites in a patient with type 1 diabetes

Abstract

We present a case of vitiligo associated with lipohypertrophy in a patient with type 1 diabetes on Lantus and Novorapid subcutaneous insulin. The patient, a 55‐year‐old woman, was diagnosed with type 1 diabetes 53 years ago. Following 11 years using Novorapid and Lantus she developed lipohypertrophy at her injection sites with associated depigmentation of the skin. The depigmentation has recurred following changing injection sites. We believe this is the first case of its kind to be reported in the literature and teaches a valuable lesson about the importance of examining injection sites. Copyright © 2016 John Wiley & Sons.

Isomorphic (Koebner) Phenomenon Induced by Insulin Analogue Injections in Psoriasis

“…This relates to the classical isomorphic response. Koebner phenomenon has already been described at insulin injection sites in diabetic patients with underlying dermatological diseases, such as vitiligo or lichen sclerosus atrophicus [ 7 , 8 ]. To the best of our knowledge, there are only two other cases describing Koebner phenomenon in patients with psoriasis following insulin injections.…”

Vitiligo associated with polycaprolactone-based collagen stimulator filler

“…The intradermal injection of insulin and antigens has been shown to induce the Koebner phenomenon in the psoriasis model but has been rarely reported in vitiligo. 8 Hedges et al 9 reported the first case of intradermal insulin injection–induced vitiligo and lipohypertrophy. Chemical leukoderma is a condition in which the chemical substance of a particular product induces the loss of pigment in the contact area.…”